CY1124976T1 - Μεθοδοι χορηγησης τετραϋδροβιοπτερινης, σχετικες συνθεσεις και μεθοδοι μετρησης - Google Patents
Μεθοδοι χορηγησης τετραϋδροβιοπτερινης, σχετικες συνθεσεις και μεθοδοι μετρησηςInfo
- Publication number
- CY1124976T1 CY1124976T1 CY20221100115T CY221100115T CY1124976T1 CY 1124976 T1 CY1124976 T1 CY 1124976T1 CY 20221100115 T CY20221100115 T CY 20221100115T CY 221100115 T CY221100115 T CY 221100115T CY 1124976 T1 CY1124976 T1 CY 1124976T1
- Authority
- CY
- Cyprus
- Prior art keywords
- methods
- tetrahydrobiopterin
- administration
- measurement
- related compositions
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4891—Coated capsules; Multilayered drug free capsule shells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B63/00—Purification; Separation; Stabilisation; Use of additives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6848—Methods of protein analysis involving mass spectrometry
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/62—Detectors specially adapted therefor
- G01N30/72—Mass spectrometers
- G01N30/7233—Mass spectrometers interfaced to liquid or supercritical fluid chromatograph
-
- H—ELECTRICITY
- H01—ELECTRIC ELEMENTS
- H01J—ELECTRIC DISCHARGE TUBES OR DISCHARGE LAMPS
- H01J49/00—Particle spectrometers or separator tubes
- H01J49/004—Combinations of spectrometers, tandem spectrometers, e.g. MS/MS, MSn
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
- Y10T436/145555—Hetero-N
- Y10T436/147777—Plural nitrogen in the same ring [e.g., barbituates, creatinine, etc.]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Nutrition Science (AREA)
- Hematology (AREA)
- Physiology (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Immunology (AREA)
- Bioinformatics & Computational Biology (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
Abstract
Η παρούσα εφεύρεση κατευθύνεται σε μεθόδους θεραπείας χορήγησης τετραϋδροβιοπτερίνης, συμπεριλαμβανομένων από του στόματος μορφών δοσολογίας, σε ενδοφλέβια σκευάσματα και μαζί με τρόφιμα. Επίσης αποκαλύπτονται στο παρόν δοκιμασίες βιοπτερίνης για μέτρηση της ποσότητας της βιοπτερίνης και μεταβολιτών βιοπτερίνης σε ένα δείγμα.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US92282107P | 2007-04-11 | 2007-04-11 | |
US1975308P | 2008-01-08 | 2008-01-08 | |
EP08745614A EP2139485B1 (en) | 2007-04-11 | 2008-04-11 | Methods of administering tetrahydrobiopterin, associated compositions, and methods of measuring |
EP12005352.5A EP2545939B1 (en) | 2007-04-11 | 2008-04-11 | Tetrahydrobiopterin for treating conditions associated with elevated phenylalanine levels |
PCT/US2008/060041 WO2008128049A2 (en) | 2007-04-11 | 2008-04-11 | Methods of administering tetrahydrobiopterin, associated compositions, and methods of measuring |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1124976T1 true CY1124976T1 (el) | 2022-11-25 |
Family
ID=39620159
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20131100024T CY1113543T1 (el) | 2007-04-11 | 2013-01-09 | Μεθοδοι χορηγησης τετραϋδροβιοπτερινης, οι σχετικες ενωσεις και οι μεθοδοι μετρησης |
CY20211100082T CY1123764T1 (el) | 2007-04-11 | 2021-02-01 | Τετραϋδροβιοπτερινη για θεραπεια καταστασεων που σχετιζονται με αυξημενα επιπεδα φαινυλαλανινης |
CY20221100115T CY1124976T1 (el) | 2007-04-11 | 2022-03-08 | Μεθοδοι χορηγησης τετραϋδροβιοπτερινης, σχετικες συνθεσεις και μεθοδοι μετρησης |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20131100024T CY1113543T1 (el) | 2007-04-11 | 2013-01-09 | Μεθοδοι χορηγησης τετραϋδροβιοπτερινης, οι σχετικες ενωσεις και οι μεθοδοι μετρησης |
CY20211100082T CY1123764T1 (el) | 2007-04-11 | 2021-02-01 | Τετραϋδροβιοπτερινη για θεραπεια καταστασεων που σχετιζονται με αυξημενα επιπεδα φαινυλαλανινης |
Country Status (23)
Country | Link |
---|---|
US (6) | US7612073B2 (el) |
EP (4) | EP4029519A1 (el) |
JP (2) | JP2010523708A (el) |
KR (5) | KR101721198B1 (el) |
CN (1) | CN101678025A (el) |
AU (1) | AU2008240259C1 (el) |
BR (1) | BRPI0809470A2 (el) |
CA (1) | CA2682598C (el) |
CY (3) | CY1113543T1 (el) |
DE (1) | DE22154751T1 (el) |
DK (3) | DK3461503T3 (el) |
ES (3) | ES2906582T3 (el) |
HK (1) | HK1139864A1 (el) |
HR (3) | HRP20220188T3 (el) |
HU (2) | HUE053107T2 (el) |
IL (1) | IL201101A (el) |
LT (2) | LT3461503T (el) |
MX (1) | MX2009010977A (el) |
PL (3) | PL2545939T3 (el) |
PT (3) | PT2545939T (el) |
RU (1) | RU2486899C2 (el) |
SI (2) | SI2545939T1 (el) |
WO (1) | WO2008128049A2 (el) |
Families Citing this family (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BRPI0416566A (pt) | 2003-11-17 | 2007-01-23 | Biomarin Pharm Inc | tratamento de fenilcetonúrias com bh4 |
EP4029519A1 (en) | 2007-04-11 | 2022-07-20 | BioMarin Pharmaceutical Inc. | Tetrahydrobiopterin for treating conditions associated with elevated phenylalanine levels |
ES2736730T3 (es) * | 2008-08-12 | 2020-01-07 | Orpha Swiss Gmbh | Forma de administración farmacéutica que contiene tetrahidrobiopterina |
EP2456432B1 (en) | 2009-07-22 | 2024-02-28 | University of Massachusetts | Compositions to reduce oxidative stress |
US20130197000A1 (en) | 2010-04-22 | 2013-08-01 | Nihon University | Drug and food/drink for preventing or improving cerebral dysfunction |
EP2646031B9 (en) * | 2010-12-03 | 2018-01-10 | Orexigen Therapeutics, Inc. | Increasing drug bioavailability in naltrexone therapy |
CA2828685C (en) * | 2011-03-01 | 2018-05-29 | Rubicon Research Private Limited | Stable compositions of tetrahydrobiopterin |
US9549563B2 (en) | 2011-10-24 | 2017-01-24 | Kickass Candy Llc | Sweet tart energy tablet |
US9216178B2 (en) * | 2011-11-02 | 2015-12-22 | Biomarin Pharmaceutical Inc. | Dry blend formulation of tetrahydrobiopterin |
ES2758446T3 (es) | 2012-01-23 | 2020-05-05 | Sage Therapeutics Inc | Formulaciones de esteroides neuroactivos que comprenden un complejo de alopregnanolona y sulfobutil éter beta-ciclodextrina |
ES2897671T3 (es) | 2012-01-26 | 2022-03-02 | Vanda Pharmaceuticals Inc | Sincronización del ritmo circadiano desincrónico del cortisol |
US11918557B2 (en) | 2012-01-26 | 2024-03-05 | Vanda Pharmaceuticals Inc. | Treatment of circadian rhythm disorders |
CN102650621B (zh) * | 2012-05-02 | 2014-06-25 | 安徽农业大学 | 一种从蚕体提取的墨蝶呤的鉴定方法 |
WO2014124392A1 (en) * | 2013-02-08 | 2014-08-14 | University Of Iowa Research Foundation | Diagnostic tools to predict onset of preeclampsia |
US10376487B2 (en) | 2013-11-12 | 2019-08-13 | Vanda Pharmaceuticals Inc. | Method of treatment |
US11090285B2 (en) | 2013-11-12 | 2021-08-17 | Vanda Pharmaceuticals Inc | Treatment of circadian rhythm disorders |
US20150204834A1 (en) * | 2014-01-22 | 2015-07-23 | Sarfaraz K. Niazi | Thermodynamic equivalence surrogate test (test) for bioequivalence |
RS54973B1 (sr) * | 2014-03-31 | 2016-11-30 | Vasopharm Gmbh | Čvrste farmaceutske kompozicije koje uključuju derivate biopterina i upotreba takvih kompozicija |
MA41124A (fr) * | 2014-12-05 | 2017-10-10 | Sun Pharmaceutical Ind Ltd | Compositions en suspension à libération prolongée à rétention gastrique |
WO2017061663A1 (ko) | 2015-10-06 | 2017-04-13 | 주식회사 지트리비앤티 | 티모신 베타 4를 포함하는 안약의 제조방법 |
CA3017172C (en) | 2016-03-08 | 2023-03-14 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
US11072614B2 (en) * | 2016-11-29 | 2021-07-27 | Ptc Therapeutics Mp, Inc. | Polymorphs of sepiapterin and salts thereof |
CA3043499A1 (en) * | 2016-11-29 | 2018-06-07 | Censa Pharmaceuticals Inc. | Polymorphic form of sepiapterin |
CN108627576A (zh) * | 2017-03-17 | 2018-10-09 | 武汉宏韧生物医药科技有限公司 | 一种人血浆中他达拉非的定量分析方法 |
JP7414529B2 (ja) | 2017-06-07 | 2024-01-16 | シファメド・ホールディングス・エルエルシー | 血管内流体移動デバイス、システム、および使用方法 |
EP3648760A1 (en) * | 2017-07-06 | 2020-05-13 | Treeway TW001 B.V. | Use of edaravone in oral treatment of oxidative-stress mediated neurodegenerative disorders |
CA3079245A1 (en) * | 2017-07-13 | 2019-03-21 | Tab Protein, Llc | Supplement tablet and packaging |
JP2020532535A (ja) | 2017-09-01 | 2020-11-12 | ピーティーシー セラピューティクス エムピー,インコーポレイテッド | セピアプテリンを含む医薬組成物及びその使用 |
US11511103B2 (en) | 2017-11-13 | 2022-11-29 | Shifamed Holdings, Llc | Intravascular fluid movement devices, systems, and methods of use |
CN110461332A (zh) * | 2017-11-20 | 2019-11-15 | 麦迪贝肯有限公司 | 制备和分析血浆中的荧光化合物的方法 |
CN109946412B (zh) * | 2017-12-21 | 2021-10-15 | 上海产业技术研究院 | 一种体液蝶呤谱检测试剂盒及其使用 |
US10722631B2 (en) | 2018-02-01 | 2020-07-28 | Shifamed Holdings, Llc | Intravascular blood pumps and methods of use and manufacture |
CN110269099B (zh) * | 2018-03-16 | 2023-01-31 | 共生地球生物科技有限公司 | 多重pH缓冲配方与蛋白质消化助剂的组合物及其用途 |
EP3766356A4 (en) * | 2018-03-16 | 2021-11-24 | Eco-Geo Bio-Technology Company Limited | MULTI-PH BUFFER FORMULATION AND COMPOSITION TO FACILITATE PROTEIN DIGESTION, AND USE OF THEM |
CN112543758A (zh) * | 2018-05-30 | 2021-03-23 | Ptc医疗Mp公司 | 墨蝶呤的药学上可接受的盐 |
BR112020024329A2 (pt) * | 2018-05-30 | 2021-02-23 | Ptc Therapeutics Mp, Inc. | composições e métodos para aumentar exposição de plasma de tetra-hidrobiopterin |
AU2019277382A1 (en) * | 2018-05-30 | 2021-01-21 | Ptc Therapeutics Mp, Inc. | Methods for increasing sepiapterin plasma exposure |
CN108813410B (zh) * | 2018-07-06 | 2021-12-14 | 浙江工商大学 | 一种降低发酵香肠中生物胺的方法及其应用 |
JP2020068734A (ja) * | 2018-11-01 | 2020-05-07 | 国立大学法人東京工業大学 | Sprをコードするポリヌクレオチドを含む組換えベクター、及びそれを含む組成物 |
CN110174363A (zh) * | 2019-01-09 | 2019-08-27 | 北京九强生物技术股份有限公司 | 6-磷酸葡萄糖脱氢酶突变体及其在制备检测试剂中的用途 |
US20200276200A1 (en) * | 2019-02-28 | 2020-09-03 | Clark Gerald Sullivan | Treatment of cns and developmental disorders using high-dose 5-formyl-(6s)-tetrahydrofolate |
US11964145B2 (en) | 2019-07-12 | 2024-04-23 | Shifamed Holdings, Llc | Intravascular blood pumps and methods of manufacture and use |
EP3999013A4 (en) * | 2019-07-15 | 2023-07-26 | R.P. Scherer Technologies, LLC | SOFT GEL CAPSULE WITH ENTERIC PROTON PUMP INHIBITOR |
WO2021016372A1 (en) | 2019-07-22 | 2021-01-28 | Shifamed Holdings, Llc | Intravascular blood pumps with struts and methods of use and manufacture |
TR201914416A1 (tr) * | 2019-09-23 | 2021-04-21 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Sapropteri̇n di̇hi̇droklorürün efervesan formülasyonlari |
EP4034192A4 (en) | 2019-09-25 | 2023-11-29 | Shifamed Holdings, LLC | INTRAVASCULAR BLOOD PUMP SYSTEMS AND METHODS OF USE AND CONTROL THEREOF |
CN111505179B (zh) * | 2020-04-07 | 2021-07-13 | 厦门大学 | 海洋水体中生物蝶呤的检测方法 |
CN112057423A (zh) * | 2020-10-21 | 2020-12-11 | 兆科药业(广州)有限公司 | 一种含有盐酸沙丙蝶呤的颗粒剂药物及其制备方法 |
CN112697919B (zh) * | 2020-12-22 | 2023-02-28 | 北京和合医学诊断技术股份有限公司 | 度洛西汀的检测方法 |
US20240115573A1 (en) * | 2021-03-26 | 2024-04-11 | Emory University | Managing the Acute and Long-Term Effects of Coronaviral Infections and Compositions Related Thereto |
CN113607870B (zh) * | 2021-07-22 | 2024-06-21 | 中国食品药品检定研究院 | 一种头孢羟氨苄原料药及其制剂中聚合物杂质的检测方法 |
CN114814036B (zh) * | 2022-05-09 | 2024-02-20 | 上海谱锐赛思生物技术有限公司 | 血浆中阿齐沙坦和氨氯地平浓度的测定方法 |
WO2024084421A1 (en) * | 2022-10-18 | 2024-04-25 | Qrgenetics Ltd. | Treatment of vascular diseases associated with genetic variations in acta2 |
Family Cites Families (56)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6019A (en) * | 1849-01-09 | Cast-iron car-wheel | ||
US6021A (en) * | 1849-01-09 | Cast-iron cab-wheel | ||
US2601215A (en) | 1948-03-17 | 1952-06-17 | American Cyanamid Co | Process of preparing dihydropterins |
US3505329A (en) | 1968-02-06 | 1970-04-07 | Smithkline Corp | Process for the synthesis of biopterin |
JPS5883691A (ja) | 1981-11-13 | 1983-05-19 | Kanegafuchi Chem Ind Co Ltd | 1′,2′−ジアシル−(6r,s)−5,6,7,8−テトラヒドロ−l−ビオプテリンおよびその製法 |
JPS5925323A (ja) | 1982-03-03 | 1984-02-09 | 鐘淵化学工業株式会社 | プテリン誘導体からなる脳内神経伝達物質の関わる疾病の治療剤 |
JPS5921685A (ja) | 1982-07-28 | 1984-02-03 | Suntory Ltd | L―エリスロ―バイオプテリンの製造法 |
GB8318833D0 (en) | 1983-07-12 | 1983-08-10 | Wellcome Found | Chemical compounds |
JPS5976086A (ja) | 1982-09-20 | 1984-04-28 | ザ ウエルカム フアウンデ−シヨン リミテツド | プテリジン化合物 |
US5196533A (en) | 1983-04-11 | 1993-03-23 | South Alabama Medical Science Foundation, Usa | Cyclization of 5 amino-pyrimidines to quinoid 6,6 disubstituted dihydropteridines |
US4587340A (en) | 1983-09-19 | 1986-05-06 | Burroughs Wellcome Co. | Biopterin analogs |
JPS60178887A (ja) | 1984-02-23 | 1985-09-12 | Kanegafuchi Chem Ind Co Ltd | 5,6,7,8−テトラヒドロ−l−ビオプテリンの製造法 |
JPS60199889A (ja) | 1984-03-24 | 1985-10-09 | Kanegafuchi Chem Ind Co Ltd | 5,6,7,8−テトラヒドロ−l−エリスロ−ビオプテリンの硫酸塩およびその製法 |
US4550109A (en) * | 1984-05-31 | 1985-10-29 | The Board Of Regents, The University Of Texas System | Lipoidal biopterin compounds |
DE3437944A1 (de) | 1984-10-17 | 1986-07-31 | Biotest-Serum-Institut Gmbh, 6000 Frankfurt | Verwendung von pterinen zur steigerung der aktivitaet von lymphokinen und anderen blutfaktoren, sowie ein diagnostisches oder therapeutisches praeparat, das pterine in kombination mit lymphokinen enthaelt |
CA1262347A (en) | 1985-01-28 | 1989-10-17 | Suntory Limited | Preparation process of (6r)-tetrahydro-l-biopterin |
JPS61277618A (ja) | 1985-06-04 | 1986-12-08 | Suntory Ltd | 自閉症治療剤 |
JPS621688A (ja) * | 1985-06-28 | 1987-01-07 | Nippon Kokan Kk <Nkk> | ばら積船 |
WO1987001038A1 (en) * | 1985-08-22 | 1987-02-26 | Commonwealth Scientific And Industrial Research Or | Peptide analogues of mammalian insulin-like growth factor-1 |
EP0318926B1 (en) | 1987-11-30 | 1995-05-03 | Kabushiki Kaisha Vitamin Kenkyusyo | Intermediates for synthesizing 5,6,7,8-tetrahydro-L-erythro-biopterin and its derivatives |
JP3137333B2 (ja) | 1990-07-21 | 2001-02-19 | サントリー株式会社 | テトラヒドロビオプテリンの製法およびそれに用いる酵素 |
JP2534423B2 (ja) | 1991-12-26 | 1996-09-18 | コーネル・リサーチ・ファンデーション・インコーポレイテッド | 酸化窒素の過剰生産から生じる血管失調を阻止する阻害剤 |
US5198547A (en) | 1992-03-16 | 1993-03-30 | South Alabama Medical Science Foundation, Usa | Process for N5-formylating tetrahydropteridines |
DE4308739C1 (de) | 1993-03-19 | 1994-06-23 | Henning Berlin Gmbh | Pterinderivate, ihre Herstellung und ihre Verwendung |
US5945452A (en) | 1993-06-11 | 1999-08-31 | The Board Of Trustees Of The Leland Stanford Junior University | Treatment of vascular degenerative diseases by modulation of endogenous nitric oxide production or activity |
US5502050A (en) | 1993-11-29 | 1996-03-26 | Cornell Research Foundation, Inc. | Blocking utilization of tetrahydrobiopterin to block induction of nitric oxide synthesis |
DE69526918T2 (de) | 1994-08-05 | 2002-12-19 | Suntory Ltd., Osaka | Arzneimittel gegen spinocerebellare degeneration |
JP2711828B2 (ja) | 1996-06-25 | 1998-02-10 | 白鳥製薬株式会社 | (6r)−テトラヒドローl−バイオプテリン塩酸塩の製造法 |
US20020076782A1 (en) | 1996-07-05 | 2002-06-20 | John P.N. Rosazza | Purified nitric oxide synthase |
GB9617990D0 (en) | 1996-08-29 | 1996-10-09 | Scotia Holdings Plc | Treatment of pain |
CH693255A5 (de) | 1997-06-13 | 2003-05-15 | Eprova Ag | Verwendung von Tetrahydrofolaten in der natürlichenstereoisomeren Form zur Herstellung einer pharmazeutischenZubereitung geeignet zur Beeinflussung des Homocystein-Spiegels. |
US5922713A (en) | 1997-06-26 | 1999-07-13 | Werner; Ernst | Inhibition of nitric oxide synthase |
US6723560B2 (en) * | 1998-10-08 | 2004-04-20 | Mayo Foundation For Medical Education And Research | Using polyamide nucleic acid oligomers to engender a biological response |
DE69925225T2 (de) | 1998-02-27 | 2006-02-23 | Daiichi Suntory Pharma Co., Ltd. | Propylaxe und behandlung der arzneimittel induzierten nierenstörungen |
JP4306825B2 (ja) | 1998-02-27 | 2009-08-05 | アスビオファーマ株式会社 | インスリン抵抗性が関与する血管機能異常を伴う疾患の予防または治療剤 |
US6200758B1 (en) | 1999-02-19 | 2001-03-13 | New York State Office Of Mental Health | Phenylalanine hydroxylase gene variants, and amino acid and pterin homeostasis, in the definition, detection, treatment and prevention of psychotic, mood and personality disorders |
WO2000056328A1 (en) | 1999-03-19 | 2000-09-28 | Enos Pharmaceuticals, Inc. | Increasing cerebral bioavailability of drugs |
GB2355191A (en) | 1999-10-12 | 2001-04-18 | Laxdale Ltd | Combination formulations for fatigue, head injury and strokes |
US6544994B2 (en) | 2000-06-07 | 2003-04-08 | Eprov Ag | Pharmaceutical preparation for treating or preventing cardiovascular or neurological disorders by modulating of the activity of nitric oxide synthase |
CA2420374A1 (en) * | 2000-08-31 | 2003-02-24 | Suntory Limited | Process for production of biopterin compound |
RU2180233C1 (ru) * | 2001-06-26 | 2002-03-10 | Общество с ограниченной ответственностью "Протеиновый контур" | Способ получения жидких лекарственных форм рекомбинантных белков |
US20040058962A1 (en) * | 2002-06-14 | 2004-03-25 | Amedeo Leonardi | Phenylalkylamines and pyridylalkylamines |
DE10260263A1 (de) * | 2002-12-20 | 2004-07-15 | Biocrates Life Sciences Gmbh | Verwendung von Tetrahydrobiopterinderivaten zur Behandlung und Ernährung von Patienten mit Aminosäurestoffwechselstörungen |
EP1667656A4 (en) * | 2003-09-01 | 2011-12-28 | Mayne Pharma Int Pty Ltd | COMPOSITIONS AND METHODS OF DISTRIBUTING BIOLOGICALLY ACTIVE AGENTS |
US7732599B2 (en) | 2003-11-17 | 2010-06-08 | Biomarin Pharmaceutical Inc. | Process for preparing tetrahydrobiopterin and analogs of tetrahydrobiopterin |
WO2005065018A2 (en) | 2003-11-17 | 2005-07-21 | Merck Eprova Ag | Crystalline forms of (6r) -l-erythro-tetrahydrobiopterin dihydrochloride |
BRPI0416566A (pt) | 2003-11-17 | 2007-01-23 | Biomarin Pharm Inc | tratamento de fenilcetonúrias com bh4 |
CA2566433C (en) | 2004-05-11 | 2013-02-19 | Daiichi Asubio Pharma Co., Ltd. | Therapeutic agent for bh4-responsive hyperphenylalaninemia |
CA2601716C (en) | 2004-06-25 | 2011-05-31 | Board Of Regents, The University Of Texas System | Methods and compositions for the treatment of attention deficit hyperactivity disorder and hyperphenylalanemia |
JP2008513027A (ja) | 2004-09-17 | 2008-05-01 | バイオマリン ファーマシューティカル インコーポレイテッド | フェニルアラニンアンモニアーリアーゼの改変体および化学的に修飾された改変体 |
WO2006055511A2 (en) | 2004-11-17 | 2006-05-26 | Biomarin Pharmaceutical Inc. | Stable tablet formulation of tetrahydrobiopterin |
US20060194808A1 (en) | 2005-01-14 | 2006-08-31 | Chronorx Llc, An Alaska Limited Liability Company | Clinical applications of tetrahydrobiopterin, lipoic acid and their salts and methods of preparing tetrahydrobiopterin bis-lipoate |
JPWO2007072911A1 (ja) | 2005-12-22 | 2009-06-04 | アスビオファーマ株式会社 | 塩酸サプロプテリンの生体内吸収性を向上させた製剤 |
US20080075666A1 (en) * | 2006-08-25 | 2008-03-27 | Dudley Samuel C Jr | Methods and compositions for treating diastolic dysfunction |
WO2008103370A1 (en) * | 2007-02-22 | 2008-08-28 | Children's Hospital And Research Center At Oakland | Fatty acid formulations and methods of use thereof |
EP4029519A1 (en) | 2007-04-11 | 2022-07-20 | BioMarin Pharmaceutical Inc. | Tetrahydrobiopterin for treating conditions associated with elevated phenylalanine levels |
-
2008
- 2008-04-11 EP EP22154751.6A patent/EP4029519A1/en not_active Withdrawn
- 2008-04-11 HU HUE12005352A patent/HUE053107T2/hu unknown
- 2008-04-11 KR KR1020167014034A patent/KR101721198B1/ko active IP Right Review Request
- 2008-04-11 MX MX2009010977A patent/MX2009010977A/es active IP Right Grant
- 2008-04-11 RU RU2009141618/15A patent/RU2486899C2/ru active
- 2008-04-11 HU HUE18205446A patent/HUE058030T2/hu unknown
- 2008-04-11 WO PCT/US2008/060041 patent/WO2008128049A2/en active Application Filing
- 2008-04-11 ES ES18205446T patent/ES2906582T3/es active Active
- 2008-04-11 SI SI200832155T patent/SI2545939T1/sl unknown
- 2008-04-11 EP EP18205446.0A patent/EP3461503B9/en not_active Revoked
- 2008-04-11 PL PL12005352T patent/PL2545939T3/pl unknown
- 2008-04-11 DK DK18205446.0T patent/DK3461503T3/da active
- 2008-04-11 DE DE22154751.6T patent/DE22154751T1/de active Pending
- 2008-04-11 SI SI200832189T patent/SI3461503T1/sl unknown
- 2008-04-11 PL PL18205446T patent/PL3461503T3/pl unknown
- 2008-04-11 DK DK12005352.5T patent/DK2545939T3/da active
- 2008-04-11 JP JP2010503234A patent/JP2010523708A/ja active Pending
- 2008-04-11 LT LTEP18205446.0T patent/LT3461503T/lt unknown
- 2008-04-11 CA CA2682598A patent/CA2682598C/en active Active
- 2008-04-11 PL PL08745614T patent/PL2139485T3/pl unknown
- 2008-04-11 KR KR1020177007999A patent/KR20170037676A/ko not_active Application Discontinuation
- 2008-04-11 PT PT120053525T patent/PT2545939T/pt unknown
- 2008-04-11 ES ES12005352T patent/ES2851177T3/es active Active
- 2008-04-11 PT PT87456141T patent/PT2139485E/pt unknown
- 2008-04-11 BR BRPI0809470-5A patent/BRPI0809470A2/pt not_active Application Discontinuation
- 2008-04-11 LT LTEP12005352.5T patent/LT2545939T/lt unknown
- 2008-04-11 EP EP08745614A patent/EP2139485B1/en not_active Revoked
- 2008-04-11 PT PT182054460T patent/PT3461503T/pt unknown
- 2008-04-11 ES ES08745614T patent/ES2397746T3/es active Active
- 2008-04-11 EP EP12005352.5A patent/EP2545939B1/en not_active Revoked
- 2008-04-11 HR HRP20220188TT patent/HRP20220188T3/hr unknown
- 2008-04-11 KR KR1020167014024A patent/KR20160065998A/ko not_active Application Discontinuation
- 2008-04-11 CN CN200880011594A patent/CN101678025A/zh active Pending
- 2008-04-11 KR KR1020097023532A patent/KR20100016445A/ko active Application Filing
- 2008-04-11 DK DK08745614.1T patent/DK2139485T3/da active
- 2008-04-11 KR KR1020157016858A patent/KR20150080026A/ko not_active Application Discontinuation
- 2008-04-11 AU AU2008240259A patent/AU2008240259C1/en active Active
- 2008-12-08 US US12/329,838 patent/US7612073B2/en active Active
-
2009
- 2009-09-22 IL IL201101A patent/IL201101A/en active IP Right Revival
- 2009-10-12 US US12/577,509 patent/US7947681B2/en not_active Ceased
-
2010
- 2010-07-05 HK HK10106506.2A patent/HK1139864A1/xx not_active IP Right Cessation
-
2011
- 2011-04-29 US US13/097,223 patent/US20110281880A1/en not_active Abandoned
- 2011-11-18 US US13/299,499 patent/USRE43797E1/en active Active
-
2012
- 2012-12-27 HR HRP20121072AT patent/HRP20121072T1/hr unknown
-
2013
- 2013-01-09 CY CY20131100024T patent/CY1113543T1/el unknown
- 2013-02-06 US US13/760,156 patent/US20130237543A1/en not_active Abandoned
- 2013-05-20 JP JP2013105957A patent/JP2013163691A/ja active Pending
-
2016
- 2016-04-06 US US15/091,813 patent/US20170000793A1/en not_active Abandoned
-
2021
- 2021-02-01 CY CY20211100082T patent/CY1123764T1/el unknown
- 2021-02-11 HR HRP20210239TT patent/HRP20210239T1/hr unknown
-
2022
- 2022-03-08 CY CY20221100115T patent/CY1124976T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1124976T1 (el) | Μεθοδοι χορηγησης τετραϋδροβιοπτερινης, σχετικες συνθεσεις και μεθοδοι μετρησης | |
CY1119618T1 (el) | Ενωσεις και συνθεσεις ως ρυθμιστικα μορια της tlr δραστηριοτητας | |
CY1121882T1 (el) | Αναστολεις πυραζολυλο κινοξαλινο κινασης | |
CY1117224T1 (el) | Καινοτομος δοσολογια και σκευασμα | |
CY1118379T1 (el) | Αναστολεις ιου ηπατιτιδας c | |
CY1122466T1 (el) | Σκευασμα αντισωματος αντι il-17ra και θεραπευτικα σχηματα για την αγωγη της ψωριασης | |
CY1119252T1 (el) | Νεα παραγωγα 1-βενζυλο-3 -υδροξυμεθυλινδαζολης και χρηση αυτων στη θεραπεια νοσων που βασιζονται στην εκφραση των cx3cr1 και ρ40 | |
CY1117995T1 (el) | Δευτεριωμενα παραγωγα κατεχολαμινης και φαρμακα που περιεχουν τις εν λογω ενωσεις | |
CY1118061T1 (el) | Δικυκλικα παραγωγα heterocyclyl σαν καταστολεις κινασης (kinase) fgfr για θεραπευτικη χρηση | |
CY1122853T1 (el) | Σταθερα σκευασματα λινακλοτιδης | |
CY1116816T1 (el) | Συνθεσεις ανταγωνιστων pd-1 και μεθοδοι χρησης | |
CY1113315T1 (el) | Ιμιδαζολοκαρβοξαμιδια | |
CY1116156T1 (el) | Παραγωγα πυριμιδινης συνδεδεμενα με οξυγονο | |
CY1118350T1 (el) | Μορφες δοσολογιας για ληψη απο το στομα που περιλαμβανουν οξεικη λικαρβαζεπινη | |
CY1118725T1 (el) | Σταθερη ενωση σιδηρου-ολιγοσακχαριτη | |
CY1117331T1 (el) | Αντισωματα προσδεσης στην εξωκυτταρικη περιοχη 4 του ανθρωπινου csf1r και η χρηση αυτων | |
CY1118099T1 (el) | Δισκια οξεικης ουλιπρισταλης | |
NI201500059A (es) | Inhibidores de la tirosina-quinasa de bruton | |
UY31639A1 (es) | Derivados de amida espirocíclica de fórmula i, sales farmacéuticamente aceptables, composiciones farmacéuticas conteniéndolas, procesos de preparación y aplicaciones | |
CY1117326T1 (el) | Παραγωγο κατεχολαμινης χρησιμο για τη θεραπεια ασθενειας parkinson | |
CY1113048T1 (el) | Παραγωγα στυρυλοπυριδινης και η χρηση τους για συνδεση κι απεικονιση πλακων αμυλοειδους | |
UA106636C2 (uk) | Морфолінотіазоли як позитивні алостеричні модулятори альфа 7 | |
EA200900044A1 (ru) | Замещенные производные 1,3-дифенилпропана, получение и их применение | |
EA200870421A1 (ru) | Димеры производных артемизинина, их получение и их применение в терапии | |
CY1117909T1 (el) | Φαρμακευτικη συνθεση που περιλαμβανει ολμεσαρτανη μεδοξομιλη και ροσουβαστατινη ή το αλας της |